Product Details
- Trelegy Ellipta 200/62.5/25 mcg is a prescription-only, once-daily inhalation powder for long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults.
- This triple-therapy inhaler combines fluticasone furoate, umeclidinium bromide, and vilanterol to target airway inflammation, bronchoconstriction, and airflow limitation in a single device.
- Delivered via the Ellipta dry powder inhaler, it provides 30 pre-measured doses designed for accurate, convenient once-daily use.
- Trelegy Ellipta 200/62.5/25 mcg is intended for ongoing control of chronic respiratory symptoms and is not suitable for relief of sudden breathing problems.
Key Features:
- Triple-Combination Therapy: Contains an inhaled corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium bromide), and a long-acting beta2 agonist (vilanterol) to provide comprehensive maintenance treatment for asthma and COPD.
- Once-Daily Dosing: Designed to be taken as one inhalation once daily at the same time each day to support consistent symptom control.
- 200/62.5/25 mcg Strength: Provides 200 mcg fluticasone furoate, 62.5 mcg umeclidinium, and 25 mcg vilanterol per inhalation for patients who require higher anti-inflammatory support.
- Ellipta Inhaler Device: Uses the Ellipta dry powder inhaler with a simple open-click-inhale-close sequence and an integrated dose counter that counts down from 30 doses.
- 30-Dose Pack: Each inhaler contains 30 pre-measured doses, offering approximately one month of therapy when used once daily as prescribed.
- Indicated for Adults: Approved for maintenance treatment of asthma and COPD in adults; not recommended for use in children under 18 years of age.
- Non-Rescue Inhaler: Not intended to treat acute asthma attacks or sudden breathing problems and does not replace a rescue inhaler.
- Established Safety Profile: Includes important safety considerations such as potential for thrush, pneumonia risk in COPD, cardiovascular effects, and hypersensitivity reactions, requiring use under medical supervision.
- Storage Guidance: Recommended to be stored below 30°C and used within its shelf life as specified by regulatory guidance.
- Prescription-Only Medicine: Classified as a prescription-only (Schedule 4) medicine and should be used only on the advice and monitoring of a healthcare professional.
